Black Rock Inc. Aim Immuno Tech Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Black Rock Inc. holds 698,267 shares of AIM stock, worth $104,740. This represents 0.0% of its overall portfolio holdings.

Number of Shares

698,267

Previous 698,333 0.01%

Holding current value

$104,740

Previous $328,000 21.34%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.35 - $0.61 $23 - $40	-66 Reduced 0.01%	698,267 $258,000
Q1 2024 May 10, 2024	SELL	$0.33 - $0.48 $3,126 - $4,547	-9,473 Reduced 1.34%	698,333 $328,000
Q4 2023 Feb 13, 2024	BUY	$0.4 - $0.56 $64 - $89	160 Added 0.02%	707,806 $311,000
Q3 2023 Nov 13, 2023	BUY	$0.44 - $0.71 $44 - $72	102 Added 0.01%	707,646 $325,000
Q2 2023 Aug 11, 2023	SELL	$0.4 - $0.67 $43,833 - $73,420	-109,583 Reduced 13.41%	707,544 $474,000
Q1 2023 May 12, 2023	BUY	$0.32 - $0.77 $1,088 - $2,618	3,401 Added 0.42%	817,127 $351,000
Q4 2022 Feb 13, 2023	BUY	$0.31 - $0.6 $82 - $159	266 Added 0.03%	813,726 $252,000
Q3 2022 Nov 14, 2022	SELL	$0.57 - $0.81 $1,847 - $2,626	-3,242 Reduced 0.4%	813,460 $473,000
Q2 2022 Aug 12, 2022	SELL	$0.78 - $1.27 $9,235 - $15,038	-11,841 Reduced 1.43%	816,702 $638,000
Q1 2022 May 12, 2022	SELL	$0.67 - $1.18 $3,859 - $6,796	-5,760 Reduced 0.69%	828,543 $878,000
Q4 2021 Feb 10, 2022	BUY	$0.92 - $1.96 $5,653 - $12,044	6,145 Added 0.74%	834,303 $767,000
Q3 2021 Nov 09, 2021	BUY	$1.91 - $2.17 $10,443 - $11,865	5,468 Added 0.66%	828,158 $1.67 Million
Q2 2021 Aug 11, 2021	BUY	$1.93 - $2.39 $1.59 Million - $1.97 Million	822,690 New	822,690 $1.77 Million

Others Institutions Holding AIM

# of Institutions

Shares Held

4.75M

Call Options Held

Put Options Held

View Full List

About AIM ImmunoTech Inc.

Ticker AIM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,049,300
Market Cap $7.21M
Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...

More about AIM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account